ECOR electroCore

electroCore, Inc. Announces Extension of NHS England’s Innovation and Technology Payment (ITP) Program to Fund Continued Use of gammaCore™ in England

electroCore, Inc. Announces Extension of NHS England’s Innovation and Technology Payment (ITP) Program to Fund Continued Use of gammaCore™ in England
EN
01/10/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on electroCore

 PRESS RELEASE

electroCore to Participate in the 25th Annual Needham Virtual Healthca...

electroCore to Participate in the 25th Annual Needham Virtual Healthcare Conference ROCKAWAY, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the Needham Virtual Healthcare Conference taking place virtually on April 15, 2026. Joshua Lev, Interim President and Chief Financial Officer, will host a company presentation at 2:15 pm ET and participate in one-on-one meetings throughout the day. DATE: April 15, 2026TIME: 2:15 pm ET Investors attending t...

 PRESS RELEASE

electroCore Announces First Patient Enrollment in Investigator-Led Stu...

electroCore Announces First Patient Enrollment in Investigator-Led Study of gammaCore™ nVNS for PTSD ROCKAWAY, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today the enrollment of the first eight patients in a clinical study being conducted by Acacia Clinics in collaboration with the Vagus Nerve Society. As previously announced, the study is designed to evaluate the safety and effectiveness of electroCore’s gammaCore™ non-invasive vagus nerve stimulation (nVNS) device as an adjunctive ...

 PRESS RELEASE

electroCore Announces Publication in Frontiers in Neuroscience Highlig...

electroCore Announces Publication in Frontiers in Neuroscience Highlighting Benefits of Non-Invasive Vagus Nerve Stimulation in Patients with Mild Traumatic Brain Injury and PTSD ROCKAWAY, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today the publication of new clinical findings in Frontiers in Neuroscience titled “Adjunctive non-invasive vagus nerve stimulation for chronic mild traumatic brain injury with comorbid post-traumatic stress disorder: a post-hoc analysis” by Drs. Michael Am...

 PRESS RELEASE

electroCore Announces Inducement Grants under NASDAQ Listing Rule 5635...

electroCore Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) ROCKAWAY, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Seth Abrams will join electroCore, effective April 1, 2026, as the Company’s VP, Sales, and Michael Fox will join electroCore, effective April 13, 2026, as the Company's Chief Operating Officer. The Compensation Committee of electroCore’s Board of Directors granted 30,000 restricted stock units (“RSUs”) to Mr. Abrams and 70,000 R...

 PRESS RELEASE

electroCore Expands Intellectual Property Portfolio

electroCore Expands Intellectual Property Portfolio electroCore strengthens its extensive intellectual property portfolio with issuance of two new U.S. patents, extending protection on core products and applications ROCKAWAY, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the issuance of two new U.S. patents that further bolster the Company’s already extensive intellectual property portfolio. These additions underscore electroCore’s position as a leader in non-invasive vagus nerve...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch